

# CITATION REPORT

List of articles citing

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment

DOI: 10.1182/blood-2011-11-393934  
Blood, 2012, 120, 2679-89.

**Source:** <https://exaly.com/paper-pdf/53149509/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
102	Molecular targeted approaches in mantle cell lymphoma. <b>2011</b> , 48, 214-26		17
101	New molecular targets in mantle cell lymphoma. <b>2011</b> , 21, 335-46		33
100	SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt. <b>2013</b> , 6, 18		19
99	Pharmacophore modeling, homology modeling, and in silico screening reveal mammalian target of rapamycin inhibitory activities for sotalolol, glyburide, metipranolol, sulfamethizole, glipizide, and pioglitazone. <b>2013</b> , 42, 39-49		35
98	mTOR kinase inhibitors as potential cancer therapeutic drugs. <b>2013</b> , 340, 1-8		110
97	Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. <b>2013</b> , 329, 45-58		17
96	CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. <b>2013</b> , 24, 631-44		306
95	Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. <b>2013</b> , 17, 921-36		11
94	Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways. <b>2013</b> , 2,		5
93	Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration. <b>2013</b> , 3, 93		10
92	A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin. <b>2013</b> , 24, 889-98		22
91	Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target. <b>2013</b> , 27, 1996-2005		14
90	SYK regulates mTOR signaling in AML. <b>2013</b> , 27, 2118-28		37
89	Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma. <b>2013</b> , 8, e73175		17
88	Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors. <b>2014</b> , 3, 832-40		15
87	Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies. <b>2014</b> , 166, 336-51		36
86	PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway. <b>2014</b> , 25, 1129-40		36

85	Emodin enhances ATRA-induced differentiation and induces apoptosis in acute myeloid leukemia cells. <b>2014</b> , 45, 2076-84	21
84	Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting. <b>2014</b> , 20, 2400-9	74
83	Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma. <b>2014</b> , 14, 335-42	55
82	Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. <b>2014</b> , 142, 164-75	520
81	Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis. <b>2014</b> , 28, 2197-205	47
80	Rictor/mammalian target of rapamycin 2 regulates the development of Notch1 induced murine T-cell acute lymphoblastic leukemia via forkhead box O3. <b>2014</b> , 42, 1031-40.e1-4	13
79	Targeting PI3K/AKT/mTOR network for treatment of leukemia. <b>2015</b> , 72, 2337-47	143
78	Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia. <b>2015</b> , 16, 648-56	28
77	Tumor microenvironment: Sanctuary of the devil. <b>2015</b> , 368, 7-13	380
76	Targeting novel signaling pathways for resistant acute myeloid leukemia. <b>2015</b> , 114, 397-402	42
75	Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin. <b>2016</b> , 16, 288-304	33
74	Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang. <b>2016</b> , 13, 248-59	75
73	B Cell Receptor Activation Predominantly Regulates AKT-mTORC1/2 Substrates Functionally Related to RNA Processing. <b>2016</b> , 11, e0160255	2
72	Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?. <b>2016</b> , 91, 507-17	17
71	Targeting the mTOR Pathway in Leukemia. <b>2016</b> , 117, 1745-52	40
70	Phospho-Inositol-3-Kinase Activity and Dysregulation in Pediatric Leukemia and Lymphoma. <b>2016</b> , 181-229	
69	PI3K-mTOR in Cancer and Cancer Therapy. <b>2016</b> ,	3
68	mTORC signaling in hematopoiesis. <b>2016</b> , 103, 510-8	20

67	New era of integrated cancer biomarker discovery using reverse-phase protein arrays. <b>2016</b> , 31, 35-45	27
66	Immunocapture strategies in translational proteomics. <b>2016</b> , 13, 83-98	28
65	Targeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidence. <b>2016</b> , 7, 40-51	42
64	CXCL12 promotes glycolytic reprogramming in acute myeloid leukemia cells via the CXCR4/mTOR axis. <b>2016</b> , 30, 1788-92	21
63	Discovery of FZU-03,010 as a self-assembling anticancer amphiphile for acute myeloid leukemia. <b>2017</b> , 27, 1007-1011	8
62	Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas. <b>2017</b> , 102, 755-764	20
61	Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia. <b>2017</b> , 21, 705-714	22
60	Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia. <b>2017</b> , 65, 36-58	27
59	Leukemic stem cells: identification and clinical application. <b>2017</b> , 105, 549-557	53
58	References. <b>2017</b> , 257-312	
57	High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. <b>2017</b> , 102, 1537-1548	10
56	Inhibition of Autophagic Degradation Process Contributes to Claudin-2 Expression Increase and Epithelial Tight Junction Dysfunction in TNF- $\alpha$ -Treated Cell Monolayers. <b>2017</b> , 18,	25
55	Impact on Autophagy and Ultraviolet B Induced Responses of Treatment with the MTOR Inhibitors Rapamycin, Everolimus, Torin 1, and pp242 in Human Keratinocytes. <b>2017</b> , 2017, 5930639	10
54	Stem cell manipulation, gene therapy and the risk of cancer stem cell emergence. <b>2017</b> , 4, 67	20
53	Dual inhibition of mTORC1/2 by DCZ0358 induces cytotoxicity in multiple myeloma and overcomes the protective effect of the bone marrow microenvironment. <b>2018</b> , 421, 135-144	5
52	Autophagy as a pharmacological target in hematopoiesis and hematological disorders. <b>2018</b> , 152, 347-361	8
51	The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth. <b>2018</b> , 46, 579-590	10
50	Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia. <b>2018</b> , 109, 103-111	20

49	Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML. <b>2018</b> , 32, 235-248	37
48	Metabolite identification and pharmacokinetic profiling of PP242, an ATP-competitive inhibitor of mTOR using ultra high-performance liquid chromatography and mass spectrometry. <b>2018</b> , 1072, 244-251	9
47	Synthesis and biological evaluation of rapamycin-derived, next generation small molecules. <b>2018</b> , 9, 27-43	10
46	Impact of immune suppressive agents on the BK-Polyomavirus non coding control region. <b>2018</b> , 159, 68-76	8
45	An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function. <b>2018</b> , 74, 68-74	10
44	miR-99a-5p acts as tumor suppressor via targeting to mTOR and enhances RAD001-induced apoptosis in human urinary bladder urothelial carcinoma cells. <b>2018</b> , 11, 239-252	33
43	The Induction of a Permissive Environment to Promote T Cell Immune Evasion in Acute Myeloid Leukemia: The Metabolic Perspective. <b>2019</b> , 9, 1166	9
42	Targeting Metabolic Reprogramming in Acute Myeloid Leukemia. <b>2019</b> , 8,	24
41	Targeting Leukemia Stem Cell-Niche Dynamics: A New Challenge in AML Treatment. <b>2019</b> , 2019, 8323592	14
40	Long non-coding RNA linc00239 promotes malignant behaviors and chemoresistance against doxorubicin partially via activation of the PI3K/Akt/mTOR pathway in acute myeloid leukaemia cells. <b>2019</b> , 41, 2311-2320	17
39	Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. <b>2019</b> , 19, 431-440.e13	25
38	Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells. <b>2020</b> , 39, 1198-1212	15
37	Autophagy modulators for the treatment of oral and esophageal squamous cell carcinomas. <b>2020</b> , 40, 1002-1060	21
36	Evaluation of the antitumor effects of PP242 in a colon cancer xenograft mouse model using comprehensive metabolomics and lipidomics. <b>2020</b> , 10, 17523	3
35	Chemo/radiotherapy-Induced Bone Marrow Niche Alterations. <b>2021</b> , 39, 180-194	2
34	Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence. <b>2020</b> , 9,	20
33	Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia. <b>2020</b> , 191, 231-242	1
32	Targeting apoptosis in cancer therapy. <b>2020</b> , 17, 395-417	389

31	Glycine Enhances Satellite Cell Proliferation, Cell Transplantation, and Oligonucleotide Efficacy in Dystrophic Muscle. <b>2020</b> , 28, 1339-1358	12
30	Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia. <b>2020</b> , 10, 1544-1565	13
29	RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma. <b>2020</b> , 10, 1004-1019	7
28	Upregulation of AKR1C1 in mesenchymal stromal cells promotes the survival of acute myeloid leukaemia cells. <b>2020</b> , 189, 694-706	4
27	Dissecting molecular mechanisms of resistance to NOTCH1-targeted therapy in T-cell acute lymphoblastic leukemia xenografts. <b>2020</b> , 105, 1317-1328	8
26	Examining the evidence of non-monotonic dose-response in Androgen Receptor agonism high-throughput screening assay. <b>2021</b> , 410, 115338	0
25	Dual Kinase Targeting in Leukemia. <b>2021</b> , 13,	1
24	Polystyrene microplastics induce an immunometabolic active state in macrophages. <b>2021</b> , 1	3
23	Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia. <b>2021</b> , 11, 673213	0
22	Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes. <b>2021</b> , 11, 705627	0
21	Extracellular ATP and CD39 activate cAMP-mediated mitochondrial stress response to promote cytarabine resistance in acute myeloid leukemia.	1
20	Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF- $\beta$ 38-ALDH2 pathway. <b>2020</b> , 15, e0242809	3
19	MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells. <b>2016</b> , 7, 55083-55097	23
18	CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma. <b>2016</b> , 7, 73558-73572	41
17	The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study. <b>2017</b> , 8, 52269-52280	18
16	Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells. <b>2017</b> , 8, 5895-5908	32
15	Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome. <b>2017</b> , 8, 23073-23086	21
14	PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242. <b>2017</b> , 8, 39185-39197	11

- 13 The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. **2015**, 6, 37930-47 26
- 12 Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells. **2013**, 4, 830-43 39
- 11 Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance?. **2021**, 13, 2
- 10 Signaling Landscape of AML: The Story So Far. **2018**, 233-262
- 9 Targeting the mTORC2 signaling complex in B cell malignancies.
- 8 Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype in AML cells through TGF- $\beta$ 38-ALDH2 pathway.
- 7 Role of inflammation and inflammatory mediators in colorectal cancer. **2014**, 125, 358-72; discussion 372-3 34
- 6 [Advances in leukemia inhibitors targeting PI3K/AKT/mTOR pathway]. **2015**, 36, 888-93
- 5 Therapeutic resistance to FLT3 inhibition is driven by a novel ATM/mTOR pathway regulating oxidative phosphorylation.
- 4 Reverse phase protein arrays in acute leukemia: investigative and methodological challenges.. **2021**, 1-11
- 3 Combination of mTOR inhibitor PP242 and AMPK activator metformin exerts enhanced inhibitory effects on colorectal carcinoma cells *in vitro* by blocking multiple kinase pathways. *Journal of Chemotherapy*, 1-11 2.3
- 2 Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM/mTOR pathway regulating oxidative phosphorylation. 11, 0
- 1 Activation of orphan receptor GPR132 induces cell differentiation in acute myeloid leukemia. **2022**, 13, 0